AVITA Medical enters exclusive distribution deal for collagen dermal matrix with Regenity Biosciences

AVITA Medical, Inc.

Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.
AVITA to pay $2M upon 510(k) clearance, up to $3M more by Jan 4, 2026 contingent on clinical results.
Revenue sharing: 50% of avg sales price first 2 years, then 60% in subsequent years.
AVITA to commercialize under its brand in US, EU, Australia, Japan; clinical studies planned for 2025.
CEO Jim Corbett says collaboration strengthens portfolio and may establish new standard of care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.